Successful rapid rituximab desensitization in an adolescent patient with nephrotic syndrome: Increase in number of Treg cells after desensitization.

& Immunology (AAAAI)/Food Allergy Initiative, the Gerber Foundation, the Dorothy and Frank Robins Family, the National Peanut Board, the Howard Gittis Memorial 3rd Year/4th Year Fellowship/Instructor Award (to J.A.B.), and the Wallace Research Foundation (grant no. WRF2010.01). Additional support for the project was provided by the National Center for Research Resources (NCRR, grant no. UL1RR024128), a component of the NIH and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or the NIH. Disclosure of potential conflict of interest: A. W. Burks is on the board for the AAAAI, the NIH’s HAI (Human-Animal Interaction) Study Section, the Food Allergy & Anaphylaxis Network, the US Food and Drug Administration’s Food Advisory Committee, the Anaphylaxis Network Research Advisory Board, and the Merck US Allergy Immunotherapy Allergist Advisory Board; has received consultancy fees from ActoGeniX, Curalogic, Dow AgroSciences, McNeill Nutritionals, Merck & Co, Novartis Pharma AG, Sanofi-Aventis US, Schering-Plough, and Unilever; is employed by Duke University Medical Center and UNC Children’s Hospital; has received one or more grants from or has one or more grants pending with the NIH and the Wallace Research Foundation; has received one or more payments for lecturing from or is on the speakers’ bureau for Abbott Laboratories and Mylan Specialty; has one or more patents (planned, pending, or issued) (US5558869, US5973121, US6441142, US6835824, US7485708, US7879977); has received payment for educational presentations development from Current Views 2012; and has stock/stock options in Allertein. S. M. Jones is a Board member for the Food Allergy & Anaphylaxis Network; has received one or more grants from or has one or more grants pending with the NIH, the Food Allergy & Anaphylaxis Network, and the National Peanut Board; has received one or more payments for lecturing from or is on the speakers’ bureau for Abbot Nutrition International, the Kentucky Society for Allergy, Asthma, & Immunology, the New England Allergy Society, the American College of Allergy, Asthma & Immunology, the Indiana University Medical School and Riley Children’s Hospital, the Spanish Society of Allergy & Clinical Immunology, and the Oregon Allergy Asthma & Immunology Society; is a member of the NIAID Safety Monitoring Committee and the Arkansas Medicaid Drug Review Committee, and an NIAID Study Section. E. H. Kim has received one or more consulting fees or honoraria from and has consultancy arrangements with Triangle E Technologies. M. D. Kulis has been supported by one or more grants from the NIH, is employed by Duke University and the University of North Carolina at Chapel Hill, and has received an NRSA Fellowship Award from the NIH. A. M. Scurlock has received one or more grants from or has one or more grants pending with the NIH. P. Varshney has been supported by an NIH T32 Training Grant and has received support for travel from the AAAAI. B. P. Vickery has been supported by one or more grants from the NIH, the AAAAI, the Food Allergy Initiative, the Gerber Foundation, the Dorothy and Frank Robins Family, the Nartional Peanut Board, and the Wallace Research Foundation and has received one or more grants from or has one or more grants pending with the NIH-NAIAD and the Foundation of the American College of Allergy, Asthma, and Immunology. The rest of the authors declare that they have no relevant conflicts of interest.